Lakeshore Hospital Unlisted Shares Annual Reports

Lakeshore Hospital Unlisted Shares

```text The document is the 28th Annual Report of Lakeshore Global Lifecare for the financial year 2023-2024. **Board of Directors & Key Personnel:** * Lists the names of the Chairman (Dr. Vayalil Parambath Shamsheer), Vice Chairman (Mr. P.M Sebastian), Managing Director (Mr. S K Abdulla), other directors, the Chief Financial Officer (Mr. Gireesh Kumar E), and the Company Secretary (Mr. R Muraleedharan). **Chairman's Message:** * The company achieved a total income of ₹403 crores and a net profit of ₹44 crores for the year ended March 31, 2024. * A dividend of ₹1.70 per share (17%) has been recommended. * The hospital provided healthcare services to 3,40,852 out-patients and 20,932 in-patients. The number of international patients increased to 20,074. * Major revenue contributors were Nephrology, Medical Oncology, Orthopedics, GI Surgery, Neuro Surgery, Urology & Transplant, Cardiology, and Surgical Oncology. * The Kozhikode Medical Centre provided healthcare to over 24,000 patients, compared to 12,000 in the previous year. * Importance was given to digitalization, including AI Chat GPT, digitalized invoices, and WhatsApp payment gateways. * ₹66 lakhs were spent on CSR activities related to education, care for women, preventive healthcare, senior citizens, and oncology patients, including the "Ammakkoru Karuthal" project. * Concessions in treatment charges amounted to ₹12.67 crores for needy patients. **Notice for Annual General Meeting:** * The 28th Annual General Meeting will be held on Saturday, the 28th of September 2024 at 12:00 Noon (IST) through Video Conferencing (VC). * The agenda includes adoption of accounts, declaration of dividend, re-appointment of directors (Mr. Job Varghese and Mr. Kaivilayil Varghese Johny), and remuneration to cost auditor (M/s BBS & Associates). * Also on the agenda is the appointment of Mr. Reuben George Joseph as an Independent Director for 3 years until August 07, 2027. * Mr. Hari Mohan Haritas will be appointed as Director * The register of members and share transfer books will be closed from September 22, 2024 to September 28, 2024 for dividend payment. * Members are requested to furnish their PAN to the Company for TDS on dividend; non-resident shareholders can avail tax treaty benefits by providing necessary documents. * Details of unpaid dividends have been uploaded on the company website. * Members holding shares in physical form are requested to consider converting to dematerialized form. **CDSL E-Voting System:** * The AGM will be held through Video Conferencing (VC) as per MCA circulars. * Remote e-voting will be available to members through Central Depository Services (India) Limited (CDSL). * Members can join the AGM in VC/OAVM mode 15 minutes before the meeting. * The facility of participation at the EGM/AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis * The Remote e-voting period commences on September 25, 2024 (9:00 AM) and ends on September 27, 2024 (5:00 PM). * Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility. * Instructions are provided for individual shareholders holding securities in Demat mode (CDSL/NSDL) and for those holding shares in physical mode. **Statement Relating to Special Business:** * Details regarding the remuneration payable to the Cost Auditor (M/s BBS & Associates) for the financial year ending 31.03.2025, which requires shareholder ratification. * Information on the appointment of Mr. Reuben George Joseph as an Independent Director, including his qualifications, experience, and compliance with Companies Act, 2013 requirements. * The appointment of Mr Hari Mohan Haritas as Director of the Company who has significant experience in the financial roles **Details of Directors Seeking Appointment/Re-appointment:** * Provides details (date of birth, qualifications, experience, etc.) for Mr. Job Varghese and Mr. Kaivilayil Varghese Johny, who are up for re-appointment. **Directors' Report:** * The Directors present the 28th Annual Report and audited financial statements for the year ended March 31, 2024. * Financial Highlights: Details of Standalone and Consolidated financial results for the year ended 31.03.2024 including Income from Operations, Net Profit. The Company has made profit before tax of ₹5501 lakhs as against ₹8242 lakhs of the previous year * Dividend: The Board recommends a dividend of ₹1.70 (17%) per equity share, subject to shareholder approval, which will result in an outflow of ₹17 cr. * Share Capital: Authorised Capital remains unchanged at ₹100 crores. * Operations Review: The hospital's patient inflow and market share have gained momentum. The hospital managed to improve service quality, cost control, and infection control practices. * Transplantations Program's success rate is over 95%. * The hospital is expanding international patient agreements (e.g., with "Aasandha" for Maldives patients). Collaborations with Bangladesh are underway. There is a tie-up in Kyrgyzstan and efforts to increase visibility in CSI countries. * Renovations and new services are ongoing, including a Labour Suite and NICU. * The Hospital treated over 340852 outpatients and treated over 20932 inpatients and performed over 191 organ transplantations, which include 163 renal and 28 liver surgeries in 2023-24. Number of Dialysis Conducted is 19654 dialysis in 2023-24. The number of international patients availing treatment in the year 23-24 is 20074 * Peripheral Gastroenterology clinics and Lakeshore IVF clinic have started. * Focus is on developing various Centers of Excellence and oncology. * Outlook: Company achieved a turnover of ₹402.89 crores (last year ₹424.45 crores) and made a net profit of ₹43.89 crores (last year ₹57.52 crores). Projected turnover for the year 2024-25 is ₹503.72 crores. * Board Composition: The Board consists of the Chairman, Managing Director, two Independent Directors, and eight non-executive directors. Names of directors retiring by rotation and those being appointed are mentioned. * Board Meeting: 4 Board Meetings were held on 24th June 2023, 14th August 2023, 5th December 2023 and 18th March 2024 * A Statement Regarding the Audit Committee, Remuneration Committee, CSR Committee and their composition is given. * Loans, Guarantees, or Investments: The company did not give any Loan or Guarantee or provide any security or make investment * Risk Management: The Company has identified the risks/uncertainty associated with the company and developed and implemented a Risk Management. * Dematerialisation: The Company has entered into agreement with NSDL and CDSL to enable Members to have the option of holding and dealing the shares of the Company in electronic form. **Compliance & Other Information:** * Confirmation of compliance with Secretarial Standards. * Details of energy conservation, technology absorption, and foreign exchange earnings and outgo. Foreign exchange earning was ₹28.78 crores (₹12.06 crores) and out go was *14.47 crores (₹5.01 crores). * Statements on personnel relations, internal financial controls, material changes, and nature of business. * Confirmation of an Internal Complaints Committee as per the Sexual Harassment of Women at Workplace Act. * Directors express gratitude to stakeholders. **Financial Statements & Annexures:** * AOC-1: Form for statement of subsidiaries (Lakeshore Food and Beverages Private Ltd). * Annexure II: Salient features of the Nomination and Remuneration Policy. * Annexure III: Annual Report on CSR activities. * Annexure IV: Form AOC-2, details of contracts/arrangements/transactions. * Annexure V: Secretarial Audit Report. * Independent Auditor's Report (Standalone and Consolidated). * Standalone and Consolidated Balance Sheets, Statements of Profit and Loss, Statements of Cash Flow, and Statements of Changes in Equity, along with related notes. ```

Lakeshore Hospital Unlisted Shares

The following is a comprehensive summary of the provided PDF document: **Overview:** The PDF is the 27th Annual Report for VPS Lakeshore, covering the financial year 2022-2023. It includes the Chairman's Message, notice of the Annual General Meeting, Directors' Report, Consolidated Financial Statements, and other compliance-related information. **Chairman's Message:** The Chairman, Dr. Vayalil Parambath Shamsheer, expresses satisfaction with the company's performance. The company achieved a total income of ₹424 crores (17% increase) and a net profit of ₹58 crores (34% increase). Earnings per share increased from ₹4.29 to ₹5.75. A dividend of ₹1.70 per share (17%) was approved. The hospital delivered healthcare services to 343,876 out-patients and 21,087 in-patients. The number of foreign patients increased significantly from 6,008 to 20,047. Key revenue contributors were Nephrology, Medical Oncology, Cardiology, Neuro Surgery, Orthopedics, Urology, transplant, and GI Surgery. 53 live liver donor transplantations and 212 renal transplantations were completed with a success rate of over 95%. Future plans include adding robotic surgery systems, a new MRI and CT, automation of patient feedback, converting manual patient files to electronic medical records (EMR), and exploring expansion in other Kerala districts. The Kozhikode Medical Centre served over 12,000 patients. Approximately ₹60 lakhs were spent on CSR activities, focusing on education, preventive healthcare, senior citizen support, and oncology patient support. ₹9.08 crores were provided in treatment concessions to needy patients. **Notice of Annual General Meeting:** The 27th Annual General Meeting will be held on September 29, 2023, via video conferencing. Ordinary business includes adopting accounts, report of directors, declaring dividend, and re-appointment of directors (Mr. K N Prabhakaran Nair and Mr. MM Mathai). Special business includes remuneration to cost auditors (M/s BBS & Associates, Kochi, ₹1,25,000 plus tax) and approval of remuneration to Managing Director (Sri S K Abdulla Kunhi with gross remuneration ₹1,12,19,759). Notes detail e-voting procedures, closure of register of members (September 23-29), communication regarding email registration, and procedures for shareholders. **Directors' Report:** The Directors present the 27th Annual Report and audited financial statements. The report provides financial highlights comparing standalone and consolidated figures for FY 2022-23 and 2021-22. A dividend of 17% (₹1.70 per share) has been recommended. The authorized capital remained at ₹100 crores. The report reviews operations, noting the difficulties in the healthcare sector during 2022-23 due to COVID-19 and nurse migration. The hospital increased capacity and utilized digital platforms to address challenges. Operational excellence highlights include treating 20,025 inpatients and 333,622 outpatients, performing 7588 surgeries and 257 organ transplantations, increasing referral patients, and conducting 21,118 dialysis, and 5,038 preventive health check-ups. A new high throughput chemistry and immunology Modular Analyser for sample testing was installed. Clinical excellence includes 16 students clearing the DNB. Super speciality DNB programs for Neurosurgery and critical care medicine were approved. The report details various awards and accolades received. Information Technology initiatives include AI Chat GPT implementation, invoice digitalization, HIS interface with lab machines, association with Pine Labs, bank reconciliation automation, WhatsApp payment gateway, and data security improvements. Projects include hospital block renovation, Nephrology & Urology OPD relocation, ER relocation, a Comprehensive liver care unit started, new dialysis unit, and upcoming ground floor renovation. Plans for the future focus on improving services, expanding reach through joint ventures, investing in new technologies, strengthening patient engagement, developing new programs for preventive care, and strengthening academic and training programs. **Financial Performance (Consolidated):** The report provides consolidated financial information. This includes information on Lakeshore Food and Beverages Private Ltd., the subsidiary. Turnover: ₹419.04 crores (previous year ₹358.47 crores). Net Profit: ₹57.52 crores (previous year ₹42.92 crores). Projected turnover is ₹473 crores and profit before tax ₹117 crores for 2023-24. **Board and Governance:** The board comprises the Chairman, Managing Director, two Independent Directors, and seven non-executive directors. Mr. K N Prabhakaran Nair and Mr. M M Mathai retire by rotation. Various Board and Committee meetings are detailed with attendance records. Audit, Nomination and Remuneration, and Corporate Social Responsibility Committees are described, including member composition and attendance at meetings. **Other Key Points:** The Company has implemented a Risk Management Policy. The Company has entered into agreements with NSDL and CDSL for dematerialization. The ISIN Number is INE01T101010. CSR activities are reported in detail, as per Section 135 of the Companies Act, 2013. The company focuses on eradication of hunger and malnutrition, preventive Health Care, Support for government initiatives, etc.. Information on Directors seeking appointment/re-appointment is provided as required under Secretarial Standard-2. Particulars of employees and related disclosures are given. Personnel and industrial relations were cordial. The company has an Internal Complaints Committee in compliance with the Sexual Harassment Act. The report includes annexures containing various statements and reports as required by the Companies Act, 2013 and related rules, including: Form AOC-1 for subsidiary information. Details of Related Party Transactions Credit Rating by CARE: ‘CARE A; Stable/CARE A1 [Single A; Outlook: Stable/A One]' for bank facilities. Declaration by Independent Directors confirms that they meet the criteria of independence as defined by Companies Act, 2013. **Independent Auditor's Report:** The report of the Independent Auditor's is attached. They give a true and fair view in conformity with the accounting principles generally accepted in India and Indian Accounting Standards (‘Ind AS’). They state that they have obtained all the information and explanations necessary, that proper books of account have been kept, that the Balance Sheet and Statement of Profit and Loss are in agreement with the books of account, and that the financial statements comply with the accounting standards. They also report on other legal and regulatory requirements. **In summary,** the Annual Report portrays a financially strong and growing healthcare organization committed to clinical excellence, social responsibility, and sound corporate governance. The company outlines ambitious plans for future growth and technological advancements while maintaining a commitment to providing affordable, quality healthcare.

Lakeshore Hospital Unlisted Shares

The following is a comprehensive summary of the 26th Annual Report (2021-2022) of VPS Lakeshore Global Lifecare: **Overview and Financial Performance:** * VPS Lakeshore achieved its highest ever income and net profit in its history. Total income increased by 48% to ₹362 crores, compared to ₹244 crores the previous year. Net profit increased substantially to ₹43 crores, compared to ₹8 crores the previous year. The Board of Directors recommended a dividend of ₹1.50 per share (15%). The Kozhikode project was started, and the possibility of starting centers in other districts of Kerala is being explored. * The hospital treated 264,081 out-patients and 18,236 in-patients. The international patient base increased due to eased COVID-19 travel restrictions. Major revenue contributors were Medical Oncology, Nephrology, Orthopedics, GI Surgery, and Neuro Surgery. The hospital completed 40 live liver donor transplantations and 132 renal transplantations with a success rate over 95%. The hospital is recognized as a major renal transplant center in South India. * ₹30 lakhs was spent on CSR projects, primarily related to education, preventive healthcare, sanitation, and vaccination. Concessions in treatment charges amounting to ₹8.55 crores were provided to needy patients. **Board and Management Changes:** * Mr. S.K. Abdulla was appointed as the Managing Director of the Company, effective July 18, 2022. **Annual General Meeting (AGM) and Resolutions:** * The 26th Annual General Meeting (AGM) will be held via video conferencing (VC) on September 26, 2022, at 12:00 Noon (IST). * Ordinary business includes adoption of accounts, declaration of dividend, and reappointment of directors (Dr. K.V. Johny and Mr. P.D. Mathew). Special business includes the appointment of Mr. V Venugopal and Dr. K Chitrathara as Directors and Mr. S.K. Abdulla Kunhi as the Managing Director. Remuneration to Cost Auditor requires ratification. * The register of members and share transfer books will be closed from September 20, 2022, to September 26, 2022, for dividend payment. * Shareholders can attend the AGM through VC and vote electronically. **Shareholder Information & Compliance:** * Tax Deducted at Source (TDS) will be applicable on dividend income. Shareholders must furnish their PAN to the Company or Depositories. Non-resident shareholders can avail beneficial rates under tax treaty by providing necessary documents. * Unclaimed dividends for the Financial Year ended 31st March 2021 should be claimed directly from the Company. Details of unclaimed dividends are available on the company website. * Members holding shares in physical form are encouraged to convert to dematerialized form. * The company has engaged CDSL to provide VC/OAVM facility to its shareholders for participation in the e-AGM. **Director Details and Remuneration:** * Details of directors seeking appointment/re-appointment are provided, including Mr. K.V. Johny, Mr. P.D. Mathew and Mr S K Abdulla Kunhi. * Mr. S.K. Abdulla's remuneration as Managing Director is detailed, including basic salary (₹8,43,000 per month) and other allowances (₹1,68,600 per month), perquisites, and other benefits. The board is authorized to pay remuneration exceeding the limits prescribed under the Companies Act, 2013. **Corporate Social Responsibility (CSR):** * CSR activities were mainly focused on eradication of hunger and malnutrition, preventive health care, supporting government initiatives in healthcare, sanitation, and promoting education. * The CSR Committee consists of Shri. A Janardhana Pai, Dr. K V Johny, and Mr. V Venugopal. **Other Key Points:** * The Directors' Responsibility Statement is included, affirming compliance with accounting standards and proper record-keeping. * The Auditors' Report does not contain any qualification, reservation, or adverse remark. * The Board has appointed M/s BVR & Associates Company Secretaries LLP as the Secretarial Auditors for the financial year 2022-23. The Secretarial Audit Report is annexed. * Credit Rating agency CARE has maintained the 'CARE A-minus' rating with stable outlook for the company's long term bank facilities. * The Company has an Internal Complaints Committee for sexual harassment cases and complied with the relevant Act. * The company is required to report on transactions with related parties in compliance with accounting standards, and related details were given. **Financial Data:** * Income from Operations ₹35847 lakhs * Other Income ₹317 lakhs * Gross Income ₹36164 lakhs * Gross Operating Profit ₹8484 lakhs * Finance Charges ₹257 lakhs * Depreciation ₹2146 lakhs * Profit before tax ₹6081 lakhs * Provision for tax ₹1790 lakhs * Profit for the year ₹4291 lakhs * Total Liabilities ₹7629.92 Lakhs * Total Equity ₹33127.68 Lakhs * Total Assets ₹46396.48 Lakhs This summary provides a high-level overview of the document, capturing the key information and points of emphasis within the 2021-2022 annual report.

Lakeshore Hospital Unlisted Shares

The following is a comprehensive summary of the Lakeshore Hospital and Research Centre Limited Annual Report for 2020-2021: **Overview:** The report covers the company's performance during a challenging year due to the COVID-19 pandemic, detailing financial results, key operational activities, and future outlook. It also includes details regarding the Annual General Meeting, director appointments, and compliance with various regulations. The company was incorporated in 1996, started functioning in 2003, and this is the 19th year of operations. **Chairman's Message:** * Acknowledges the impact of the COVID-19 pandemic on the healthcare sector, including reduced patient visits. * Highlights the company's designation as an approved vaccination center and its support of the government's vaccination drive. * Reports total income from operations as ₹244.42 crores (compared to ₹306.63 crores the previous year) and profit for the year as ₹7.75 crores (compared to ₹16.44 crores). * Board recommended a 5% dividend to shareholders, subject to approval. * Details healthcare delivery to 126,137 out-patients and 9,721 in-patients. * Projects a turnover of ₹320 crores and a profit before tax of ₹25.00 crores for the current financial year (2021-22). * Announces the commencement of operations at the Kozhikode Medical Centre from September 2nd, 2021. * Reports CSR spending of ₹37 lakhs, focusing on preventive healthcare, sanitation, and COVID-related expenditure. * Highlights the provision of ₹3.56 crores in treatment concessions to needy patients. **Annual General Meeting:** * The 25th AGM will be held on December 9th, 2021, via video conferencing. * Ordinary business includes the adoption of accounts, declaration of dividend, and re-appointment of directors (Mr. Job Varghese and Mr. M.M. Mathai). * A special business resolution proposes the re-appointment of Dr. Vayalil Parambath Shamsheer as the Managing Director. * Notice details procedures for e-voting and participation in the virtual meeting. * The notice also covers changes of address, TDS on dividend, and unclaimed dividend. **Directors' Report:** * Highlights the financial results for the year ended March 31, 2021, including both standalone and consolidated figures. * Standalone income from operations was ₹242.31 crores, with a profit of ₹7.76 crores. * Recommends a 5% dividend. * Reports no changes in the authorized share capital. * Reviews operations, noting the impact of COVID-19 and the measures taken to overcome challenges. * Discusses the launch of the Comprehensive Liver Care Clinic and the start of operations at Kozhikode Medical Centre. * Projects a turnover of ₹296 crores and profit before tax of ₹9.37 crores for FY 2021-22. * States that the company has not accepted/renewed fixed deposits during the year under consideration. * The Board consists of the Chairman and Managing Director, two Independent Directors including a woman director, and six non-executive directors. * Lists details of Board meetings and attendance. * Covers details on Audit Committee, Nomination and Remuneration Committee, Corporate Social Responsibility Committee. * States the company did not give any Loan or Guarantee or provide any security or make investment covered under Section 186 of the Companies Act, 2013 during the year. * States that formal annual evaluation was conducted and recorded by the Board of its own performance. * States that Annual Return in the prescribed format is available on the website of the Company at the link www.vpslakeshorehospital.com under Investor Zone. * CARE Agency, maintained the 'CARE A-minus' rating with stable outlook for the Company's long term bank facilities 'CARE A2+' for the Company's short term bank facilities. * The letter of appointment of Independent Directors have been placed on the Company’s website. **Detailed Financial Information & Notes:** * Includes standalone and consolidated balance sheets as of March 31, 2021, and March 31, 2020. * Comprehensive notes detail accounting policies, share capital, reserves and surplus, borrowings, trade payables, employee benefits, and other financial details. * Auditor’s reports by Krishnamoorthy & Krishnamoorthy for both standalone and consolidated financial statements. **Directors Responsibility Statement:** * Confirms that in the preparation of the annual accounts for the financial year ended March 31, 2021 the applicable accounting standards had been followed along with proper explanation relating to material departures; * The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period; * The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities; * The directors had prepared the annual accounts on a 'going concern basis'; and * The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively. **Key Personnel:** * Lists the Board of Directors, Chief Executive Officer (Mr. S.K. Abdulla), Chief Financial Officer (Mr. R. Narayanan), and Company Secretary (Mr. R. Muraleedharan). **Notices/Disclosures** * Annual report and AGM materials, including E-Voting instructions, will be disseminated electronically to members and available on the company website. * Information provided for Shareholders to get registered if not registered with the company’s email. * CDSL E- Voting System - for e-voting and joining virtual meetings. * All documents open for inspection for the members only in electronic format. **Appendices:** Contains additional disclosures including CSR activities, Loans, Guarantees or Investments, Risk Management Policy, Vigil Mechanism /Whistle Blower Policy, Dematerialisation, Related Party Transactions, Formal Annual Evaluation, and other disclosures.